Developed by Eli Lilly, it engages incretin receptors in the pancreas and in brain regions that regulate food intake, and in research it is studied for insulin secretion, glycemic control, appetite and body-weight reduction across the SURPASS and SURMOUNT trial programs
Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, et al
Clinical experience with semaglutide and tirzepatide shows weight typically returns after discontinuation, which supports long-term use
For the high-switch outcome (Model ii), IBS subtype was the dominant determinant (overall P=0.004) and the pseudo-R 2 revealed a moderate fit (0.29)
Research investigations commonly explore the compound in experimental models examining: Peptide signalling pathways Regulatory network interactions Peptide interaction dynamics Intracellular signalling mechanisms Comparative peptide research Molecular signalling pathway analysis Receptor interaction modelling Research Applications In controlled research environments, GHK-Cu may be utilised in experimental models designed to explore peptide signalling systems and molecular interactions